141 related articles for article (PubMed ID: 19428363)
1. Phospholipase C and sphingomyelinase activities of the Clostridium perfringens alpha-toxin.
Urbina P; Flores-Díaz M; Alape-Girón A; Alonso A; Goni FM
Chem Phys Lipids; 2009 May; 159(1):51-7. PubMed ID: 19428363
[TBL] [Abstract][Full Text] [Related]
2. Clostridium perfringens alpha-toxin: characterization and mode of action.
Sakurai J; Nagahama M; Oda M
J Biochem; 2004 Nov; 136(5):569-74. PubMed ID: 15632295
[TBL] [Abstract][Full Text] [Related]
3. Site-specific mutagenesis of Clostridium perfringens alpha-toxin: replacement of Asp-56, Asp-130, or Glu-152 causes loss of enzymatic and hemolytic activities.
Nagahama M; Nakayama T; Michiue K; Sakurai J
Infect Immun; 1997 Aug; 65(8):3489-92. PubMed ID: 9234819
[TBL] [Abstract][Full Text] [Related]
4. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C. perfringens in host tissues.
O'Brien DK; Melville SB
Infect Immun; 2004 Sep; 72(9):5204-15. PubMed ID: 15322015
[TBL] [Abstract][Full Text] [Related]
5. Structure of the key toxin in gas gangrene.
Naylor CE; Eaton JT; Howells A; Justin N; Moss DS; Titball RW; Basak AK
Nat Struct Biol; 1998 Aug; 5(8):738-46. PubMed ID: 9699639
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the calcium-binding C-terminal domain of Clostridium perfringens alpha-toxin.
Naylor CE; Jepson M; Crane DT; Titball RW; Miller J; Basak AK; Bolgiano B
J Mol Biol; 1999 Dec; 294(3):757-70. PubMed ID: 10610794
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine-57 and -65 in membrane-damaging and sphingomyelinase activities of Clostridium perfringens alpha-toxin.
Nagahama M; Otsuka A; Sakurai J
Biochim Biophys Acta; 2006 Jan; 1762(1):110-4. PubMed ID: 16278077
[TBL] [Abstract][Full Text] [Related]
8. Identification of residues in the carboxy-terminal domain of Clostridium perfringens alpha-toxin (phospholipase C) which are required for its biological activities.
Walker N; Holley J; Naylor CE; Flores-Díaz M; Alape-Girón A; Carter G; Carr FJ; Thelestam M; Keyte M; Moss DS; Basak AK; Miller J; Titball RW
Arch Biochem Biophys; 2000 Dec; 384(1):24-30. PubMed ID: 11147832
[TBL] [Abstract][Full Text] [Related]
9. A turbidometric assay for phospholipase C and sphingomyelinase.
Torley L; Silverstrim C; Pickett W
Anal Biochem; 1994 Nov; 222(2):461-4. PubMed ID: 7864373
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the C. perfringens alpha-toxin with the active site closed by a flexible loop region.
Eaton JT; Naylor CE; Howells AM; Moss DS; Titball RW; Basak AK
J Mol Biol; 2002 May; 319(2):275-81. PubMed ID: 12051905
[TBL] [Abstract][Full Text] [Related]
11. On the in vitro neutralization test of Clostridium perfringens type A toxin.
Shemanova GF; Vlasova EV; Postnikova TM
J Hyg Epidemiol Microbiol Immunol; 1988; 32(2):219-26. PubMed ID: 2900852
[TBL] [Abstract][Full Text] [Related]
12. Gene cloning shows the alpha-toxin of Clostridium perfringens to contain both sphingomyelinase and lecithinase activities.
Saint-Joanis B; Garnier T; Cole ST
Mol Gen Genet; 1989 Nov; 219(3):453-60. PubMed ID: 2560137
[TBL] [Abstract][Full Text] [Related]
13. In vitro aggregation of platelets induced by alpha-toxin (phospholipase C) of Clostridium perfringens.
Sugahara T; Takahashi T; Yamaya S; Ohsaka A
Jpn J Med Sci Biol; 1976 Oct; 29(5):255-63. PubMed ID: 189107
[TBL] [Abstract][Full Text] [Related]
14. Role of Clostridium perfringens phospholipase C in the pathogenesis of gas gangrene.
Flores-Díaz M; Alape-Girón A
Toxicon; 2003 Dec; 42(8):979-86. PubMed ID: 15019495
[TBL] [Abstract][Full Text] [Related]
15. Structure of the gangrene alpha-toxin: the beauty in the beast.
Derewenda ZS; Martin TW
Nat Struct Biol; 1998 Aug; 5(8):659-62. PubMed ID: 9699620
[TBL] [Abstract][Full Text] [Related]
16. Hemolytic and sphingomyelinase activities of Clostridium perfringens alpha-toxin are dependent on a domain homologous to that of an enzyme from the human arachidonic acid pathway.
Titball RW; Leslie DL; Harvey S; Kelly D
Infect Immun; 1991 May; 59(5):1872-4. PubMed ID: 1902199
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases.
Schoepe H; Pache C; Neubauer A; Potschka H; Schlapp T; Wieler LH; Baljer G
Infect Immun; 2001 Nov; 69(11):7194-6. PubMed ID: 11598102
[TBL] [Abstract][Full Text] [Related]
18. In silico, in vitro and in vivo analysis of binding affinity between N and C-domains of Clostridium perfringens alpha toxin.
Uppalapati SR; Kingston JJ; Qureshi IA; Murali HS; Batra HV
PLoS One; 2013; 8(12):e82024. PubMed ID: 24349173
[TBL] [Abstract][Full Text] [Related]
19. Isolation of alpha-toxin, theta-toxin and kappa-toxin mutants of Clostridium perfringens by Tn916 mutagenesis.
Awad MM; Rood JI
Microb Pathog; 1997 May; 22(5):275-84. PubMed ID: 9160297
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase C hydrolysis of phospholipids in bilayers of mixed lipid compositions.
Ruiz-Argüello MB; Goñi FM; Alonso A
Biochemistry; 1998 Aug; 37(33):11621-8. PubMed ID: 9709000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
